Fortrea Holdings Inc.
FTREHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeFortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. At a $2.25B market cap, Fortrea Holdings Inc. ranks as a mid-cap company within healthcare. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Market Cap
$2.25B
Beta
1.91
P/E (TTM)
—
P/E (Fwd)
20.89
EPS (TTM)
$-0.91
EPS (Fwd)
$1.13
ROE
-15.3%
ROA
0.6%
Cash
$168.6M
Total Debt
$1.12B
Free CF
$278.9M
52W Change
127.4%
Annual Financials
Cash vs Debt
Where FTRE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FTRE finished 39.95% above its 150-day moving average ($16.02) and 45.49% above its 200-day moving average ($15.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FTRE overbought or oversold?
At the October 20, 2026 close, FTRE's RSI(14) was 72.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $168.6M in cash, though total debt stands at $1.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $278.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -15.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.6% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.06B to $2.72B.
Fortrea Holdings Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Fortrea Holdings Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fortrea Holdings Inc. and its sector.